Multimodality therapy in stage III non-small cell lung cancer

Annals of Thoracic Surgery

Volumn 61, Issue 5, 1996, Pages 1564-1572

  Edelman, Martin J ^a   Gandara, David R ^b   Roach III, Mack ^b   Benfield, John R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MITOMYCIN; VINBLASTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER STAGING; HUMAN; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0029920798     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00044-6     Document Type: Review

References (60)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. Ca 1995;45:8-30.
2. Mountain CF. The new international system for staging lung cancer. Chest 1986;89:225S-33S.
3. Van Raemdonck D, Schneider A, Ginsberg R. Surgical treatment for higher stage non-small cell lung cancer. Ann Thorac Surg 1992;54:999-1013.
4. Pearson FG, DeLarue NC, Livies R, et al. Significance of positive mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982;83:1-11.
5. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987;67:1037-49.
6. Bonomi P, Gale M, Faber LP et al. Is clinical stage III non-small cell lung cancer (NSCLC) a homogenous group? [Abstract]. Proc Am Soc Clin Oncol 1992;11:292.
7. DeWys W, Begg C, Lavin P, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491-7.
8. Albain KS, Crowley J, LeBlanc M, Livingston R. Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group Experience. J Clin Oncol 1991;9:1618-26.
9. Berendsen H. de Leij L, Poppema S, et al. Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989;7: 1614-20.
10. Macchiarini P, Fontanini G, Hardin M, et al. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-6.
11. Filderman AE, Silvestri GA, Gatsonis C, et al. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am Rev Respir Dis 1992;146:707-10.
12. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994;330:153-8.
13. Webb WR, Gatsonis C, Zerhouni E, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Thorac Radiol 1991;178:705-13.
14. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 4th ed. Philadelphia: Lippincott, 1993;673-723.
15. Lederle FA, Niewoehner DE. Lung cancer surgery: a critical review of the evidence. Arch Intern Med 1994;154:2397-2400.
16. Mountain CF. Expanded possibilities for surgical treatment of lung cancer: survival in stage IIIA disease. Chest 1990;97: 1045-51.
17. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable IIIA non-small cell lung cancer. J Natl Cancer Inst 1994;86:673-80.
18. Dillman RP, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung carcinoma. N Engl J Med 1990;323:940-5.
19. Sause WT, Scott C, Taylor S, et al. RTOG 8808 and ECOG 4588, preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
20. Doseretz DE, Katin MJ, Blitzer PH, et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys 1992;24:3-9.
21. Le Chevalier T, Arrigada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of a randomized trial of 353 patients. J Natl Cancer Inst 1991;83: 417-23.
22. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12:539-47.
23. Hansen HH. Advanced non-small cell lung cancer: to treat or not to treat? J Clin Oncol 1987;5:1711-2.
24. Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:794-800.
25. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-41.
26. Klastersky J. Sculier JP, Ravez P, et al. EORTC Lung Cancer Working Party (1986): a randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986;4:1780-6.
27. Ruckdeschel JC, Finkelstein DM, Mason BA, Creech RH. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation V - a randomized comparison of four cisplatin-containing regimens. J Clin Oncol 1985;3:72-9.
28. Livingston RB. Treatment of advanced non-small cell lung cancer: the Southwest Oncology Group experience. Semin Oncol 1988;15:37-41.
29. Green MR, Kramar A, Schilsky R, et al. Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol 1990;18:197-202.
30. Gandara DR, Perez EA, Wold HG, et al. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol 1990;27:243-7.
31. Raefsky EL, Wasserman TH. Combined modality therapy. In: Perry MC, ed. The chemotherapy sourcebook. Baltimore: Williams and Wilkins, 1992;110-29.
32. Roach M, Kallman R, John MJ. Alkylating agents. In: John MJ, Flam MS, Legha SS, Phillips TL, eds. Chemoradiation: an integrated approach to cancer treatment. Philadelphia: Lea & Febiger, 1993;chapter 8:90-103.
33. Cox JD. Endpoints for clinical trials in non-small cell carcinoma of the lung. Controversies in staging and treatment of locally advanced non-small cell lung cancers. IASLC Workshop, Bruges, Belgium, 1993.
34. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group Phase II Study 8805. J Clin Oncol 1995;13:1880-92.
35. Looney WB. Special lecture: alternating chemotherapy and radiotherapy. NCI Monographs 1988;6:85-94.
36. Morton RF, Jett JR, McGinnis WL, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. Ann Intern Med 1991;115:681-6.
37. Mattson K, Holsti LR, Holsti P, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988;24:477-82.
38. Mira JG, Crowley JJ, Miller TP. Chest irradiation (RT) versus chest RT plus chemotherapy ± prophylactic brain RT in localized non-small cell lung cancer: a Southwest Oncology Group randomized study [Abstract]. Proc ASTRO 1990;19: 145.
39. Gregor A, Macbeth FR, Paul J, Cram L, Hansen HH. Radical radiotherapy and chemotherapy in localized inoperable non-small cell lung cancer: a randomized trial. J Natl Cancer Inst 1993;85:12.
40. Le Chevalier T, Arrigada R, Tarare M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma [Letter]. J Natl Cancer Inst 1992;84:58.
41. Dillman RP, Seagren SL, Herndon J, et al. Randomized trial of induction chemotherapy plus radiation therapy versus RT alone in stage III non-small cell lung cancer (NSCLC): five years follow-up of CALGB 84-33 [Abstract]. Proc Am Soc Clin Oncol 1993;12:329.
42. Schaake-Konig C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992;326: 524-30.
43. Soresi E, Clerici M, Grilli T, et al. A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol 1988;15(Suppl 7):20-25.
44. Trovo MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992;24:11-5.
45. Blanke C, Ansari R, Mantravadi R, et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier oncology group protocol. J Clin Oncol 1995;13:1425-9.
46. Gandara DR, Valone FH, Perez EA, et al. Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I-II study. Int J Radiat Oncol Biol Phys 1991;20:1047-52.
47. Kubota K, Furuse K, Kawahara M, et al. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 1994;12:1547-52.
48. Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989;40:266-74.
49. Faber LP, Kittle CF, Warren WH, et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 1989;47:669-77.
50. Burkes R, Ginsberg RJ, Shepherd F, et al. Phase II pilot program of neoadjuvant chemotherapy for stage III (T1-3, N2, M0) unresectable non-small cell carcinoma of the lung [Abstract]. Lung Cancer 1988;4:A166.
51. Bonomi P, Recine D, Rowland K, Reddy S, et al. Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer 1990;66:2270-8.
52. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:1 365-74.
53. Weiden PL, Piantadosi S, for the Lung Cancer Study Group. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer: phase II study of the LCSG. J Natl Cancer Inst 1991; 83: 66-72.
54. Rusch VW, Albain KS, Crowley JJ, et al. Surgical resection of stage IIIA and stage IIIB non-small cell lung cancer after concurrent induction of chemoradiotherapy. J Thorac Cardiovasc Surg 1993;105:97-106.
55. Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA nonsmall cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992;10:1237-44.
56. Albain KS. Induction therapy followed by definitive local control for stage III non-small-cell lung cancer. Chest 1993; 103:1(43S).
57. Fleck J, Camargo J, Godoy D, et al. Chemoradiation therapy versus chemotherapy alone as a neo-adjuvant treatment for stage III non-small cell lung cancer. Preliminary results of a phase III randomized trial [Abstract]. Proc Am Soc Clin Oncol 1993;12:333.
58. Armstrong J, Burman C, Leibel S, et al. 3-Dimensional treatment planning may be superior to conventional high dose radiation therapy for locally advanced NSCLC [Abstract]. Proc Am Soc Clin Oncol 1992;11:291.
59. Weil M, Roach M, Pickett B, Young B, Kuerth S, Phillips TL. 3-D nonformal radiotherapy in the sagittal plane for centrally located thoracic tumors. Med Dosimetry 1995;20:11-4.
60. Edelman MJ, Gandara DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 1996;37:385-93.